gvtcx

Radium-223 therapy for bone metastasis from prostate cancer

Northampton General Hospital N H S Trust Published 28 Nov 2016 Contracts Finder

key details

Value£1,500,000
Statuscomplete
Category (CPV) 85000000
RegionEast Midlands
Deadline3 Dec 2016
Contract start5 Dec 2016
Contract end21 Dec 2020
Procedureselective
SME suitableYes
OCIDocds-b5fd17-06fa79dc-259f-4c60-9146-15668762fd7a

Award

SupplierValueDateStatus
Bayer PLC £2,200,000 24 Nov 2016 active

description

NGHT has had to publish a VEAT notice for the following therapy:

Xofigo (Radium 223) Dose.

The reason for the VEAT notice was due to:

"There was a palliative treatment called Strontium that could be used for bone pain, however this involved some significant side-effects and hence it has not been used for a number of years.

This new treatment (Radium 223) has been shown to significantly improve overall survival for this group of patients. (ALSYMPCA trial). Currently these patients are either sent elsewhere for the same treatment, or they do not receive treatment.

This is the only radiopharmaceutical that has been granted NICE approval for treatment of bone metastasis, and is the only Radium (223) product currently available commercially.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
22 Dec 2016 Award (award) · c5870a3f-91ee-4056-b444-6ea461521a27-122513

more from Northampton General Hospital N H S Trust

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.